also in pA-treated hippocampal cultures, resulting in mitochondrial dysfunction, which would contribute to neuronal death. In cholinergic neurons, PA impaired acetylcholine synthesis without affecting choline acetyltransferase activity, which suggests that PDH is inactivated by PA-induced TPKI/GSK-3P8. Thus (2) (3) (4) (5) , and extensive neuronal loss. The mechanisms that lead to AD pathology are not clear. However, the discovery that mutations in the gene for amyloid precursor protein linked to familial AD (6, 7) supports the amyloid hypothesis (8) , which claims that P-amyloid peptide (PA) deposition directly contributes to neurodegeneration and the formation of neurofibrillary tangles in AD brain. In primary rat hippocampal cultures, 3A exposure induces neuronal degeneration as well as aberrant tau protein phosphorylation, affording a product similar in character to paired helical filament-tau (9, 10) . We first purified protein kinases from the microtubule fraction in bovine brain (11) . One of these enzymes was named tau protein kinase I (TPKI) and was identical to the /3 isoform of glycogen synthase kinase 3 (GSK-3) (12) (13) (14) . This enzyme modified normal tau protein to a highly phosphorylated form bearing an epitope of paired helical filament and exhibiting a large shift in electrophoretic mobility, both in vitro (11) and in cells in which tau protein and TPKI/GSK-3,3 were overexpressed (15) . By using an antisense oligonucleotide, we recently obtained evidence that TPKI/ GSK-3/3 is involved in tau protein phosphorylation and neuronal death (9) . On 5-bromo-4-chloro-3-indolyl P3-D-galactoside (X-Gal) assay. The rescued cDNA plasmids were recovered from His+, P-galactosidase-positive transformants and cotransformed back into HF7c with pGBT9, so as to identify those cDNA isolates specifically positive with TPKI/GSK-313. Then the sequences of these cDNA plasmids were analyzed by using the GAL4 activation domain junction primer (Clontech).
Cell Culture. Primary rat hippocampal and septum cultures from embryonic day-18 fetuses (9) were plated at a density of 2 x 105 cells per cm2 on polylysine-coated plates in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% heat-inactivated fetal bovine serum (HyClone). After 3 days, the medium was changed to serum-free neurobasal medium (GIBCO) with B-27 (GIBCO) and L-glutamate (GIBCO) supplements. Experiments were done by using the culture at 6 to 7 days. ,3As (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) were synthesized and purified as described (9) . PA stock solution (2 mM in water) was frozen at -20°C for >24 hr and thawed at 37°C. Turbid freeze-thawed PA solution was used for each experiment.
In Vitro Phosphorylation of PDH by TPKI/GSK-3,. The a subunit of PDH was purified from porcine heart PDH complex (Sigma) according to the method described by Matuda et al. (18) . The kinase-inactivated PDH complex was prepared by pretreatment of PDH complex purified from porcine heart (Sigma) with 5 mM dichloroacetate, a specific PDH kinase inhibitor (19) , for 10 min at 37°C in kinase buffer containing 100 mM MES (pH 6.5), 0.9 mM magnesium acetate, 1 mM EGTA, 0.02% Tween 20, 10% (vol/vol) glycerol, and 5 mM 2-mercaptoethanol. TPKI/GSK-3,3 and TPKII were purified from bovine brain (11) . The purified a subunit of PDH (0.1 jig) was incubated at 30°C with or without TPKI/GSK-3j3 for 30 min in kinase buffer containing 0.5 mM ATP. The kinaseinactivated PDH complex (4.7 milliunits) was incubated with or without TPKI/GSK-3,3 or TPKII at 30°C for the indicated periods under the above condition. PDH activity was assayed by monitoring NADH production at 340 nm (20) in the reaction buffer (50 mM potassium phosphate buffer, pH 8.0/2.5 mM NAD/0.2 mM thiamine pyrophosphate/0.13 mM CoA/2.6 mM L-cysteine/5 mM pyruvate/enzyme source) using an EL340 automated microplate reader (Bio-Tek, Burlington, VT).
Immunoblotting. Subcellular fractionation of hippocampal neuronal cultures was performed by differential centrifugation according to the method described by McKeel and Jarett (21) as described (22) . Briefly, cell pellets were homogenized in a buffer (10 mM potassium phosphate, pH 7.4/1 mM EGTA/1 mM EDTA/5 mM 2-mercaptoethanol/1 mM phenylmethylsulfonyl fluoride/0.25 M sucrose). This crude homogenate (Homogenate) was centrifuged (1000 x g, 10 min) to remove undisrupted cells and nuclear fraction; about 30% of the TPKI/GSK-3,3 immunoreactivity included in the crude homogenate was removed by the centrifugation; however, the remaining 70% was exclusively recovered in fractions presented in Fig. 2A . After centrifugation (13,000 x g, 5 min) to remove particulate fraction, the supernatant was recovered as Cytoplasm, and the pellet (particulate fraction) was washed twice in the same buffer solution by centrifugation (13,000 x g, 5 min), resuspended, and centrifuged (600 x g, 5 min). The resulting supernatant was centrifuged (13, (24) . Immunogold detection of the antigen was done as described (22) . Briefly, incubation with the first antibody C-1 was performed for 1 (27) . After addition of saturated K2CO3 (final 10%), the supernatants were chilled on ice for 30 min, and centrifuged briefly. The supernatants were recovered, neutralized with HCI, filtered through a 0.22-tim membrane filter, and assayed for ACh with an HPLC-electrochemical detector system (28) using an immobilized-enzyme prepacked column (BAS-Japan, Tokyo, Japan). The determination of choline acetyltransferase (ChAT) activity was performed by Fonnum's method (29 (Fig. 1B) . These results confirmed the interaction of PDH with TPKI/ GSK-313. Another tau kinase, TPKII (11, 31) , had no effect on PDH activity (Fig. 1B) . Localization of TPKI/GSK-3P8 in Mitochondria. PDH complex is located in mitochondria. We recently found that only a single GSK-3 isoform, TPKI/GSK-3,3, was present in mitochondria in cerebellum neurons, but GSK-3a was not (22) . This isoform-specific mitochondrial localization was observed in hippocampal neurons; 8% of TPKI/GSK-33 in the initial homogenate was recovered by subcellular fractionation in the mitochondrial pellet ( Fig. 2A) , in which PDH activity was predominantly recovered, but GSK-3a was not detected in this fraction (data not shown). Immunocytochemical analyses confirmed the presence of TPKI/GSK-3,3 in mitochondria (Fig.  2B) . The PDH Inactivation by /3A-Induced TPKI/GSK-3, in Hippocampal Neuronal Cultures. Recently PDH kinase was cloned from a rat heart cDNA library (32) , but the signal cascades that lead to this kinase are unknown. TPKI/GSK-3,3 clearly differs from this PDH kinase, which lacks the general motif of eukaryotic Ser/Thr kinases and is similar to bacterial histidine kinases (32) . To test whether TPKI/GSK-33 acts as an in vivo PDH kinase, we examined the effect of 3A on PDH activity using primary cultures of rat hippocampal neurons. As shown in Fig. 3 , TPKI/GSK-3,3 activity increased rapidly on f3A treatment, reaching its maximum at 6 hr after 3A exposure, and PDH was inactivated in inverse proportion to the 3A-induced TPKI/GSK-3, activation. When TPKI/GSK-33 synthesis was blocked by antisense oligonucleotides (9), PDH activity showed a 2-to -3-fold increase, which corresponds with the fact that antisense oligonucleotides reduce the amount of TPKI/GSK-313 by 40% as compared to that in untreated cells (9) . Thus, the inactivation of PDH activity showed a good correlation with TPKI/GSK-313 activity.
3A-Induced Impairment Fig. 3 . These results suggest that TPKI/GSK-3j3 functions as an in vivo PDH regulator. Recently, we found that another isoform, GSK-3a, is not present in mitochondria (22) . Thus, regulation of PDH is a TPKI/GSK-3/3-specific function in mitochondria. In many other tissues, including liver, heart, and kidney, TPKI/GSK-33 was localized predominantly in mitochondria as determined by immunoelectron microscopy (data not shown). This result suggests that PDH regulation by TPKI/GSK-3j3 is a general physiological phenomenon.
In AD brain, PA deposition is a primary cause of AD pathogenesis (neuritic plaques, as well as neuronal and synaptic loss) (1, (6) (7) (8) 34) . From postmortem studies, PDH activity was found to be decreased in AD brain (35) (36) (37) . This decrease in PDH activity would induce the disturbed glucose metabolism (38, 39) (44) . A close relationship between changes in cortical cholinergic innervation and the development of neuritic plaque has also been reported (45) . These observations are consistent with our proposed mechanism.
In the light of our present results, TPKI/GSK-3j3 occupies a critical position in the signal cascades of 3A-induced neuronal death because in cytoplasm it catalyzes abnormal phosphorylation of tau and induces microtubule disruption, and in mitochondria it phosphorylates PDH, leading to mitochondrial dysfunction and reduced ACh synthesis. Thus, TPKI/ GSK-3j3 triggers multiple neuronal death cascades and appears to play a primary role in j3A neurotoxicity as observed in hippocampal neuronal cultures (9) . Here 
